FDA
-
-
-
-
-
-
-
Dyne Therapeutics Appoints Barry Greene to Board of Directors
-
-
-
-
-
-
-
Dyne starts phase 3 trial of muscular dystrophy drug z-rostudirsen
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN) following 2026 MDA conference
-
-
-
-
-
-
-
Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN)
-
-
-
-
-
-
-
Dyne Therapeutics names Vikram Karnani to board of directors
-
-
-
-
-
-
-
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
-
327,818 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

